PRGN-2009 is under clinical development by Precigen and currently in Phase II for Human Papillomavirus (HPV) Associated Cancer. According to GlobalData, Phase II drugs for Human Papillomavirus (HPV) Associated Cancer have a 14% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PRGN-2009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRGN-2009 is under development for the treatment of human papillomavirus (HPV positive) associated cancers such as esophageal cancer, lung cancer, vulvar cancer, rectal cancer and penile cancer, head and neck, cervical, vaginal, anal cancer and oropharyngeal cancer. It is administered through subcutaneous route. The therapeutic candidate is a vaccine that includes adenoviral vectors for efficient gene delivery for therapeutics and vaccines. It is developed based upon the AdenoVerse technology platform.
Precigen, formerly Intrexon Corp, is a clinical stage biotechnology company that develops synthetic biology solutions. It offers clinical and pre clinical products. The company clinical products include PRGN-3006, PRGN-3005, AG019, PRGN-2009, PRGN-2012 and PRGN-3007. The company’s pre clinical product portfolio comprises of PRGN-3008, PRGN-5001,PRGN-2010, PRGN-2011, PRGN-5002, PRGN-2013, AG017, PRGN-3009 and PRGN-3010. Precigen provides treatment in areas of immuno-oncology, autoimmune disorders, infectious diseases, solid tumors, celiac disease, heart failure, ovarian cancer and type 1 diabetes. It therapeutics platforms include UltraCAR-T, AdenoVerse therapies, ActoBiotics, multifunctional therapeutics, UltraVector, AdenoVerse, AttSite, UltraPorator and RheoSwitch, among others. It erves customers worldwide. Precigen is headquartered in Germantown, Maryland, the US.
For a complete picture of PRGN-2009’s drug-specific PTSR and LoA scores, buy the report here.